{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:47:08Z","timestamp":1791935228714,"version":"4.3.4"},"reference-count":348,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.survophthal.2021.05.013","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T11:27:39Z","timestamp":1622460459000},"page":"388-410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective"],"prefix":"10.1016","volume":"67","author":[{"given":"Menelaos","family":"Kanakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Petrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giota","family":"Lourida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-5865","authenticated-orcid":false,"given":"Ilias","family":"Georgalas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2021.05.013_bib0001","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2147\/OPTH.S32469","article-title":"Retinopathy associated with interferon therapy in patients with hepatitis C virus","volume":"6","author":"Abd El-Badie Mohamed","year":"2012","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"7","key":"10.1016\/j.survophthal.2021.05.013_bib0002","first-page":"3257","article-title":"Erdheim-Chester disease: a comprehensive review","volume":"34","author":"Abdelfattah","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0003","doi-asserted-by":"crossref","first-page":"360","DOI":"10.12659\/AJCR.897479","article-title":"The first reported case of Erdheim-Chester disease in Egypt with bilateral exophthalmos, loss of vision, and multi-organ involvement in a young woman","volume":"17","author":"Abdellateef","year":"2016","journal-title":"Am J Case Rep"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0004","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3928\/23258160-20150610-13","article-title":"Choroidal involvement in Erdheim-Chester disease","volume":"46","author":"Abdellatief","year":"2015","journal-title":"Ophthalmic Surg, Lasers Imaging Retina"},{"issue":"42","key":"10.1016\/j.survophthal.2021.05.013_bib0005","doi-asserted-by":"crossref","first-page":"e5167","DOI":"10.1097\/MD.0000000000005167","article-title":"Erdheim-Chester disease (ECD): Case report, clinical and basic investigations, and review of literature","volume":"95","author":"Adawi","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"13","key":"10.1016\/j.survophthal.2021.05.013_bib0006","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers","volume":"26","author":"Adjei","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0007","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1148\/rg.352140197","article-title":"Histiocytic disorders of the chest: imaging findings","volume":"35","author":"Ahuja","year":"2015","journal-title":"Radiographics"},{"issue":"12","key":"10.1016\/j.survophthal.2021.05.013_bib0008","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1007\/s00417-003-0787-5","article-title":"Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up","volume":"241","author":"Aisenbrey","year":"2003","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0009","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.mayocpiqo.2018.05.001","article-title":"Dabrafenib and Trametinib treatment for Erdheim-Chester Disease with brain stem involvement","volume":"2","author":"Al Bayati","year":"2018","journal-title":"Mayo Clinic Proc Innov Qual Outcomes"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0010","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.radcr.2020.02.020","article-title":"A case of Erdheim-Chester disease initially mistaken for retroperitoneal lymphoma","volume":"15","author":"Alduraibi","year":"2020","journal-title":"Radiol Case Rep"},{"issue":"7","key":"10.1016\/j.survophthal.2021.05.013_bib0011","first-page":"E25","article-title":"Multimodality imaging showing complete cardiovascular involvement by Erdheim-Chester disease","volume":"11","author":"Alharthi","year":"2010","journal-title":"Eur J Echocardiogr"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0012","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3171\/2009.10.SPINE09316","article-title":"Atypical spine involvement of Erdheim-Chester disease in an elderly male","volume":"12","author":"Allmendinger","year":"2010","journal-title":"J Neurosurg Spine"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0013","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000477336","article-title":"Erdheim-Chester Disease: Case Report with Aggressive Multisystem Manifestations and Review of the Literature","volume":"10","author":"Alotaibi","year":"2017","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0014","first-page":"64","article-title":"Orbital manifestations of Erdheim-Chester disease","volume":"81","author":"Alper","year":"1983","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000446845","article-title":"Risk of Ophthalmic Adverse Effects in Patients Treated with MEK Inhibitors: A Systematic Review and Meta-Analysis","volume":"57","author":"Alves","year":"2017","journal-title":"Ophthalmic Res"},{"issue":"8","key":"10.1016\/j.survophthal.2021.05.013_bib0016","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0002-9343(01)00937-8","article-title":"Cardiac tumor due to Erdheim-Chester disease","volume":"111","author":"Ammann","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0017","doi-asserted-by":"crossref","first-page":"293","DOI":"10.11604\/pamj.2019.33.293.19194","article-title":"Erdheim-Chester disease revealed by diabetes insipidus","volume":"33","author":"Amor","year":"2019","journal-title":"Pan Afr Med J"},{"issue":"10","key":"10.1016\/j.survophthal.2021.05.013_bib0018","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1111\/jdv.15636","article-title":"Sarcoidosis occurring during BRAF\/MEK inhibitors is associated with paradoxical ERK activation in Erdheim-Chester patients","volume":"33","author":"Amoura","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"20","key":"10.1016\/j.survophthal.2021.05.013_bib0019","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1182\/blood-2010-04-279240","article-title":"Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease","volume":"116","author":"Aouba","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0020","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.14694\/EdBook_AM.2014.34.e441","article-title":"Biological and therapeutic implications of the BRAF pathway in histiocytic disorders","author":"Arceci","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"10.1016\/j.survophthal.2021.05.013_bib0021","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2010-10-313510","article-title":"Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients","volume":"117","author":"Arnaud","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.survophthal.2021.05.013_bib0022","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1182\/blood-2010-06-294108","article-title":"CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients","volume":"117","author":"Arnaud","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.survophthal.2021.05.013_bib0023","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1002\/art.24848","article-title":"18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease","volume":"60","author":"Arnaud","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.survophthal.2021.05.013_bib0024","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1002\/art.27672","article-title":"Pulmonary involvement in Erdheim-Chester disease: a single-center study of thirty-four patients and a review of the literature","volume":"62","author":"Arnaud","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0025","first-page":"311","article-title":"(18)F-FDG positron emission tomography\/computed tomography and (99m)Tc-MDP skeletal scintigraphy in a case of Erdheim-Chester disease","volume":"14","author":"Asabella","year":"2011","journal-title":"Hel J Nucl Med"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0026","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jbspin.2012.07.005","article-title":"Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra","volume":"80","author":"Aubert","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0027","first-page":"37","article-title":"Erdheim Chester Disease treated successfully with cladribine","volume":"18","author":"Azadeh","year":"2016","journal-title":"Respir Med Case Rep"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0028","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/ajt.12061","article-title":"Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation.","volume":"13","author":"Barbas","year":"2013","journal-title":"Am J Transplant"},{"issue":"27","key":"10.1016\/j.survophthal.2021.05.013_bib0029","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1200\/JCO.2005.08.036","article-title":"Raf: a strategic target for therapeutic development against cancer","volume":"23","author":"Beeram","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.survophthal.2021.05.013_bib0030","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.eye.6701689","article-title":"Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab)","volume":"19","author":"Benitez-del-Castillo","year":"2005","journal-title":"Eye (London, England)"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0031","first-page":"2017","article-title":"Erdheim-Chester disease associated with a novel, complex BRAF p.Thr599_Val600delinsArgGlu mutation","author":"Bentel","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0032","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.revmed.2020.02.008","article-title":"[Use of targeting therapy in Erdheim-Chester disease: A case report with neurologic involvement]","volume":"41","author":"Berthe","year":"2020","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0033","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaa008","article-title":"Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series","author":"Bhatia","year":"2020","journal-title":"Neuro-Oncol"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0034","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1590\/S0004-27492007000500025","article-title":"[Intraocular involvement in Erdheim-Chester disease\u2013first report in the literature: case report]","volume":"70","author":"Biccas Neto","year":"2007","journal-title":"Arq Bras Oftalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2021.05.013_bib0035","doi-asserted-by":"crossref","first-page":"844","DOI":"10.7326\/0003-4819-135-9-200111060-00027","article-title":"Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation","volume":"135","author":"Boissel","year":"2001","journal-title":"Ann Intern Med"},{"issue":"13","key":"10.1016\/j.survophthal.2021.05.013_bib0036","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.survophthal.2021.05.013_bib0037","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.3324\/haematol.2019.223552","article-title":"Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation","volume":"104","author":"Bonnet","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0038","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/10428194.2020.1824070","article-title":"The triptych of mixed histiocytosis: a systematic review of 105 cases and proposed clinical classification","volume":"62","author":"Bonometti","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0039","article-title":"MAP2K1-driven mixed Langerhans cell histiocytosis, Rosai-Dorfman-Destombes disease and Erdheim-Chester disease, clonally related to acute myeloid leukemia","author":"Bonometti","year":"2020","journal-title":"J Cutan Pathol"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0040","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/imj.12685","article-title":"Does the BRAF(V600E) mutation herald a new treatment era for Erdheim-Chester disease? A case-based review of a rare and difficult to diagnose disorder","volume":"45","author":"Bosco","year":"2015","journal-title":"Intern Med J"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0041","first-page":"727","article-title":"A rare histiocytosis with severe cardiac involvement: Erdheim-Chester disease","volume":"27","author":"Botelho","year":"2008","journal-title":"Rev Port Cardiol"},{"issue":"11","key":"10.1016\/j.survophthal.2021.05.013_bib0042","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/thorax.58.11.1004","article-title":"Erdheim-Chester disease: pulmonary infiltration responding to cyclophosphamide and prednisolone","volume":"58","author":"Bourke","year":"2003","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0043","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","article-title":"Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients","volume":"24","author":"Boussemart","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0044","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/acn3.51014","article-title":"Neurological manifestations of Erdheim-Chester Disease","volume":"7","author":"Boyd","year":"2020","journal-title":"Ann Clinical Transl Neurol"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0045","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/ard.61.3.199","article-title":"Erdheim-Chester disease: typical radiological bone features for a rare xanthogranulomatosis","volume":"61","author":"Breuil","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.survophthal.2021.05.013_bib0046","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00296-011-1998-4","article-title":"Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature","volume":"32","author":"Broccoli","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0047","article-title":"Erdheim-Chester Disease: Two cases from an ophthalmic perspective","volume":"20","author":"Brodie","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"11","key":"10.1016\/j.survophthal.2021.05.013_bib0048","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s00330-010-1830-7","article-title":"Erdheim-Chester disease: CT findings of thoracic involvement","volume":"20","author":"Brun","year":"2010","journal-title":"Eur Radiol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0049","doi-asserted-by":"crossref","DOI":"10.1111\/cup.13988","article-title":"Cutaneous involvement of Erdheim-Chester Disease in a patient with Burkitt Lymphoma","author":"Buckley","year":"2021","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0050","article-title":"Teaching Neuroimages: Brain and skin involvement in Erdheim-Chester disease","author":"Budhram","year":"2020","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0051","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuchi.2018.08.002","article-title":"A case of Erdheim-Chester disease with spinal cord compression and sphenoid sinus involvement","volume":"64","author":"Bunaux","year":"2018","journal-title":"Neurochirurgie"},{"issue":"10198","key":"10.1016\/j.survophthal.2021.05.013_bib0052","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S0140-6736(19)31787-8","article-title":"Getting to the heart of the matter in a multisystem disorder: Erdheim-Chester disease","volume":"394","author":"Buono","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0053","article-title":"Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease.","author":"Campochiaro","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0054","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejim.2015.03.004","article-title":"Erdheim-Chester disease","volume":"26","author":"Campochiaro","year":"2015","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0055","article-title":"Bone lesions in Erdheim-Chester disease","author":"Ca\u00f1amero","year":"2019","journal-title":"Med Clin (Barc)"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0056","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.medcli.2019.07.015","article-title":"Bone lesions in Erdheim-Chester disease","volume":"155","author":"Ca\u00f1amero","year":"2020","journal-title":"Med Clin (Barc)"},{"issue":"8","key":"10.1016\/j.survophthal.2021.05.013_bib0057","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1136\/annrheumdis-2013-204924","article-title":"BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease","volume":"74","author":"Cangi","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0058","first-page":"735","article-title":"Neuroradiologic aspects of Chester-Erdheim disease","volume":"16","author":"Caparros-Lefebvre","year":"1995","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0059","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1947601911408079","article-title":"RAS Interaction with PI3K: More Than Just Another Effector Pathway","volume":"2","author":"Castellano","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3389\/fimmu.2014.00281","article-title":"Oncogene-induced senescence as a new mechanism of disease: the paradigm of Erdheim-Chester disease","volume":"5","author":"Cavalli","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0061","doi-asserted-by":"crossref","DOI":"10.1002\/JLB.3MR0120-203RR","article-title":"Erdheim-Chester disease: An in vivo human model of M\u03d5 activation at the crossroad between chronic inflammation and cancer","author":"Cavalli","year":"2020","journal-title":"J Leukoc Biol"},{"issue":"10","key":"10.1016\/j.survophthal.2021.05.013_bib0062","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/annrheumdis-2012-202542","article-title":"The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases","volume":"72","author":"Cavalli","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0063","first-page":"323","article-title":"Erdheim-Chester disease: The power of nuclear medicine imaging","volume":"39","author":"Cerudelli","year":"2020","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"8","key":"10.1016\/j.survophthal.2021.05.013_bib0064","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11886-020-01307-z","article-title":"Erdheim-Chester Disease: a rare but important cause of recurrent pericarditis","volume":"22","author":"Chahine","year":"2020","journal-title":"Curr Cardiol Rep"},{"issue":"26","key":"10.1016\/j.survophthal.2021.05.013_bib0065","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0066","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/17843286.2017.1290861","article-title":"A cytologic diagnosis of BRAF(V600E) Erdheim-Chester disease on pericardial fluid","volume":"72","author":"Chasseur","year":"2017","journal-title":"Acta Clin Belg"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0067","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1046\/j.1365-2141.2000.02206.x","article-title":"Sight-threatening varicella zoster virus infection after fludarabine treatment","volume":"110","author":"Chee","year":"2000","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0068","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5414\/CN107041","article-title":"Pericardial effusion as a crucial presentation of Erdheim-Chester disease in a hemodialysis patient: an overlooked diagnosis","volume":"78","author":"Chen","year":"2012","journal-title":"Clin Nephrol"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0069","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00415-017-8692-8","article-title":"Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease","volume":"265","author":"Chiapparini","year":"2018","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2014.07.003","article-title":"Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib","volume":"158","author":"Choe","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2021.05.013_bib0071","first-page":"1225","article-title":"Central nervous system toxicity of fludarabine phosphate","volume":"70","author":"Chun","year":"1986","journal-title":"Cancer Treat Rep"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.crad.2020.06.022","article-title":"Primary and secondary diseases of the perinephric space: an approach to imaging diagnosis with emphasis on MRI","volume":"76","author":"Chung","year":"2021","journal-title":"Clin Radiol"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0073","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2015.02.004","article-title":"Erdheim-Chester disease: a systematic review","volume":"95","author":"Cives","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.survophthal.2021.05.013_bib0074","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3109\/00365521.2015.1063155","article-title":"Irreversible optic neuritis after infliximab treatment in a patient with ulcerative colitis","volume":"50","author":"Clemmensen","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0075","unstructured":"Cohen-Aubart F, Benameur N, Amoura Z, Haroche J. Response to: 'Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease' by Campochiaro et\u00a0al. Ann Rheumatic Dis 2020."},{"issue":"8","key":"10.1016\/j.survophthal.2021.05.013_bib0076","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1161\/ATVBAHA.118.310803","article-title":"Hypoalphalipoproteinemia and BRAF(V600E) Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease","volume":"38","author":"Cohen-Aubart","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.survophthal.2021.05.013_bib0077","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2017-03-771873","article-title":"Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)","volume":"130","author":"Cohen Aubart","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0078","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/bjh.14284","article-title":"Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease","volume":"180","author":"Cohen Aubart","year":"2018","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.survophthal.2021.05.013_bib0079","doi-asserted-by":"crossref","first-page":"e2746","DOI":"10.1212\/WNL.0000000000010748","article-title":"Central nervous system involvement in Erdheim-Chester disease: An observational cohort study","volume":"95","author":"Cohen Aubart","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0080","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood.2020005101","article-title":"High frequency of clonal hematopoiesis in Erdheim-Chester disease","volume":"137","author":"Cohen Aubart","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0081","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5578\/tt.68541","article-title":"[A rare disease; Erdheim-Chester disease presenting with spontaneous pneumothorax]","volume":"67","author":"Co\u015fkuner","year":"2019","journal-title":"Tuberk Toraks"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0082","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1210\/jc.2015-3357","article-title":"Endocrine manifestations in a monocentric cohort of 64 patients with Erdheim-Chester disease","volume":"101","author":"Courtillot","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0083","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.radcr.2020.03.008","article-title":"Erdheim-Chester disease presenting with cough, abdominal pain, and headache","volume":"15","author":"Crivelli","year":"2020","journal-title":"Radiol Case Rep"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0084","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/rheumatology\/keaa430","article-title":"Coated aorta in Erdheim-Chester disease","volume":"60","author":"Cui","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.survophthal.2021.05.013_bib0085","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/bjo.2004.043968","article-title":"Is screening for interferon retinopathy in hepatitis C justified?","volume":"88","author":"Cuthbertson","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"28","key":"10.1016\/j.survophthal.2021.05.013_bib0086","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1200\/JCO.2012.41.9911","article-title":"Tumor necrosis factor \u03b1 as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab","volume":"30","author":"Dagna","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1104","key":"10.1016\/j.survophthal.2021.05.013_bib0087","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190473","article-title":"Cardiothoracic manifestations of Erdheim-Chester disease","volume":"92","author":"Das","year":"2019","journal-title":"Br J Radiol"},{"issue":"9","key":"10.1016\/j.survophthal.2021.05.013_bib0088","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00108-020-00849-2","article-title":"[Erdheim-Chester disease-A histiocytic multisystem disease with unusual renal involvement].","volume":"61","author":"Dasdelen","year":"2020","journal-title":"Internist (Berl)"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0089","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1586\/ecp.12.37","article-title":"New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment","volume":"5","author":"Dastiridou","year":"2012","journal-title":"Exp Rev Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0090","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.crad.2009.10.010","article-title":"Erdheim-Chester disease presenting with destruction of a metacarpal","volume":"65","author":"Davies","year":"2010","journal-title":"Clin Radiol"},{"issue":"6892","key":"10.1016\/j.survophthal.2021.05.013_bib0091","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.survophthal.2021.05.013_bib0092","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0093","first-page":"627","article-title":"Erdheim-Chester disease: MR imaging, anatomic, and histopathologic correlation of orbital involvement","volume":"25","author":"De Abreu","year":"2004","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0094","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000011714","article-title":"Teaching Video neuroimages: multisystemic Erdheim-Chester Disease presenting as a cerebellar ataxia","author":"de Brito","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0095","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12967-017-1246-0","article-title":"Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study","volume":"15","author":"de la Cruz-Merino","year":"2017","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0096","article-title":"Erdheim-Chester disease among neuroinflammatory syndromes: the case for precision medicine","volume":"7","author":"de la Fuente","year":"2020","journal-title":"Neurol(R) Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0097","first-page":"213","article-title":"[Erdheim-Chester disease: a case report].","volume":"75","author":"Delporte","year":"2020","journal-title":"Rev Med Liege"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0098","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ccm.2016.04.005","article-title":"Langerhans Cell Histiocytosis and Other Histiocytic Diseases of the Lung","volume":"37","author":"DeMartino","year":"2016","journal-title":"Clin Chest Med"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0099","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood-2014-03-561381","article-title":"Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease","volume":"124","author":"Diamond","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","article-title":"Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms","volume":"6","author":"Diamond","year":"2016","journal-title":"Cancer Discov"},{"issue":"7749","key":"10.1016\/j.survophthal.2021.05.013_bib0101","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0102","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.survophthal.2021.05.013_bib0103","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.rce.2018.07.010","article-title":"Corneal involvement due to Erdheim-Chester disease","volume":"219","author":"D\u00edez de Los R\u00edos","year":"2019","journal-title":"Rev Clin Esp"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0104","doi-asserted-by":"crossref","first-page":"omz015","DOI":"10.1093\/omcr\/omz015","article-title":"Mysterious quad of constrictive pericarditis, recurrent pleural effusions, bone involvement and interstitial lung disease","volume":"2019","author":"Ding","year":"2019","journal-title":"Oxf Med Case Reports"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1586\/17469899.3.1.97","article-title":"Ocular toxicity of fludarabine: a purine analog","volume":"3","author":"Ding","year":"2008","journal-title":"Exp Review Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0106","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2214\/ajr.183.5.1831253","article-title":"Imaging of thoracoabdominal involvement in Erdheim-Chester disease","volume":"183","author":"Dion","year":"2004","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0107","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12348-015-0049-9","article-title":"Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib","volume":"5","author":"Draganova","year":"2015","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0108","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1148\/radiol.10090320","article-title":"Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings","volume":"255","author":"Drier","year":"2010","journal-title":"Radiology"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0109","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.semcdb.2018.03.002","article-title":"Molecular characterization of the histiocytoses: Neoplasia of dendritic cells and macrophages","volume":"86","author":"Durham","year":"2019","journal-title":"Semin Cell Dev Biol"},{"issue":"12","key":"10.1016\/j.survophthal.2021.05.013_bib0110","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-019-0653-6","article-title":"Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms","volume":"25","author":"Durham","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0111","article-title":"Ocular side effects of target therapy and immunotherapy in patients with cutaneous malignant melanoma","author":"Eikenberry","year":"2020","journal-title":"Eur J Ophthalmol"},{"issue":"157","key":"10.1016\/j.survophthal.2021.05.013_bib0112","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0163-2019","article-title":"Ultra-rare cystic disease.","volume":"29","author":"Elia","year":"2020","journal-title":"Eur Respir Rev"},{"issue":"22","key":"10.1016\/j.survophthal.2021.05.013_bib0113","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0114","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2012.46.9676","article-title":"BRAF mutations in Erdheim-Chester disease","volume":"31","author":"Emile","year":"2013","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.survophthal.2021.05.013_bib0115","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2014-04-570937","article-title":"Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease","volume":"124","author":"Emile","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0116","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/bloodadvances.2016001784","article-title":"The clinical spectrum of Erdheim-Chester disease: an observational cohort study","volume":"1","author":"Estrada-Veras","year":"2017","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.survophthal.2021.05.013_bib0117","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-228280","article-title":"Vemurafenib as first-line therapy in BRAF-V600E-mutant Erdheim-Chester disease with CNS involvement","volume":"12","author":"Fern\u00e1ndez-Eulate","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0118","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1055\/s-0042-102668","article-title":"Intraocular inflammation associated with new therapies for cutaneous melanoma - case series and review","volume":"233","author":"Fierz","year":"2016","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0119","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000003531","article-title":"Central Nervous system complications of Erdheim-Chester disease: FDG PET\/CT findings","author":"Filizoglu","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0120","first-page":"619","article-title":"Erdheim-Chester disease. Case report with autopsy findings","volume":"115","author":"Fink","year":"1991","journal-title":"Arch Pathol Lab Med"},{"issue":"18","key":"10.1016\/j.survophthal.2021.05.013_bib0121","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0122","first-page":"2017","article-title":"An unusual case of interstitial lung disease in a patient with cardiopulmonary syndrome as the initial presentation of Erdheim-Chester disease","author":"Franco-Palacios","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-6420(83)34600-5","article-title":"Ocular Toxicity of Antineoplastic Agents","volume":"90","author":"Fraunfelder","year":"1983","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0124","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/jnnp.58.2.238","article-title":"Erdheim-Chester disease and slowly progressive cerebellar dysfunction","volume":"58","author":"Fukazawa","year":"1995","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"12","key":"10.1016\/j.survophthal.2021.05.013_bib0125","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.21037\/qims-19-953","article-title":"Whole body positron emission tomography-MRI of Erdheim-Chester disease: a case report","volume":"10","author":"Garbino","year":"2020","journal-title":"Quant Imaging Med Surg"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0126","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/jon.12785","article-title":"Clinical and neuroimaging manifestations of Erdheim-Chester disease: A Review","volume":"31","author":"Garg","year":"2021","journal-title":"J Neuroimaging"},{"issue":"8","key":"10.1016\/j.survophthal.2021.05.013_bib0127","first-page":"1121","article-title":"High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for adult histiocytic disorders with central nervous system involvement","volume":"91","author":"Gaspar","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0128","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2478\/raon-2018-0002","article-title":"Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib","volume":"52","author":"Gavric","year":"2018","journal-title":"Radiol Oncol"},{"issue":"8","key":"10.1016\/j.survophthal.2021.05.013_bib0129","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.3324\/haematol.2019.217794","article-title":"Shared cell of origin in a patient with Erdheim-Chester disease and acute myeloid leukemia","volume":"104","author":"Ghobadi","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.survophthal.2021.05.013_bib0130","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood-2015-01-620377","article-title":"Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial","volume":"126","author":"Gianfreda","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0131","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1182\/blood.2020008965","article-title":"CHIPping away at Erdheim-Chester disease","volume":"137","author":"Goyal","year":"2021","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.survophthal.2021.05.013_bib0132","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.2019003507","article-title":"Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era","volume":"135","author":"Goyal","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0133","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1111\/bjh.16177","article-title":"Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin","volume":"187","author":"Goyal","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0134","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.3324\/haematol.2019.234187","article-title":"Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms","volume":"105","author":"Goyal","year":"2020","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.survophthal.2021.05.013_bib0135","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jamaoncol.2017.0041","article-title":"Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease","volume":"3","author":"Goyal","year":"2017","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.survophthal.2021.05.013_bib0136","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.mayocp.2019.02.023","article-title":"The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease","volume":"94","author":"Goyal","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0137","doi-asserted-by":"crossref","first-page":"650","DOI":"10.6004\/jnccn.2020.7549","article-title":"BRAF-Mutated Erdheim-Chester Disease: Profound Response to Vemurafenib Visualized With Serial Multimodality Imaging","volume":"18","author":"Gray","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0138","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ckj\/sfu068","article-title":"Erdheim-Chester disease: from palliative care to targeted treatment","volume":"7","author":"Graziani","year":"2014","journal-title":"Clin Kidney J"},{"issue":"12","key":"10.1016\/j.survophthal.2021.05.013_bib0139","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/jamaophthalmol.2014.3024","article-title":"Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib","volume":"132","author":"Guedj","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0140","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00000441-200208000-00008","article-title":"Erdheim-Chester disease with prominent pericardial involvement: clinical, radiologic, and histologic findings","volume":"324","author":"Gupta","year":"2002","journal-title":"Am J Med Sci"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0141","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1097\/IOP.0000000000000866","article-title":"Vemurafenib (BRAF Inhibitor) Therapy for Orbital Erdheim-Chester Disease","volume":"33","author":"Gupta","year":"2017","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0142","unstructured":"Gupta AK, M AW, Meena JP, et\u00a0al. A rare presentation of Erdheim Chester disease in a pediatric patient subsequently cured on the LCH III protocol. Cancer Rep n\/a(n\/a):e1304."},{"key":"10.1016\/j.survophthal.2021.05.013_bib0143","first-page":"e1304","article-title":"A rare presentation of Erdheim Chester disease in a pediatric patient subsequently cured on the LCH III protocol","author":"Gupta","year":"2020","journal-title":"Cancer Rep (Hoboken, NJ)."},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0144","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/archopht.1993.01090030068041","article-title":"Interferon-associated retinopathy","volume":"111","author":"Guyer","year":"1993","journal-title":"Arch Ophthalmol (Chicago, Ill: 1960)"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0145","first-page":"1","article-title":"Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis","author":"Hao","year":"2018","journal-title":"J Neurosurg Pediatr"},{"issue":"11","key":"10.1016\/j.survophthal.2021.05.013_bib0146","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1182\/blood-2008-03-148304","article-title":"Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis","volume":"111","author":"Haroche","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0147","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/01.md.0000145368.17934.91","article-title":"Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review","volume":"83","author":"Haroche","year":"2004","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0148","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1210\/jc.2006-2018","article-title":"Bilateral adrenal infiltration in Erdheim-Chester disease. Report of seven cases and literature review.","volume":"92","author":"Haroche","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.survophthal.2021.05.013_bib0149","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/art.22165","article-title":"Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients","volume":"54","author":"Haroche","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0150","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.rdc.2013.02.011","article-title":"Erdheim-Chester disease","volume":"39","author":"Haroche","year":"2013","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0151","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s11926-014-0412-0","article-title":"Erdheim-Chester disease","volume":"16","author":"Haroche","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"13","key":"10.1016\/j.survophthal.2021.05.013_bib0152","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2012-05-430140","article-title":"High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses","volume":"120","author":"Haroche","year":"2012","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.survophthal.2021.05.013_bib0153","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1161\/CIRCULATIONAHA.108.825075","article-title":"Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients","volume":"119","author":"Haroche","year":"2009","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.survophthal.2021.05.013_bib0154","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/blood.2019002766","article-title":"Erdheim-Chester disease","volume":"135","author":"Haroche","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0155","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.2014.57.1950","article-title":"Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease","volume":"33","author":"Haroche","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7287","key":"10.1016\/j.survophthal.2021.05.013_bib0156","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.survophthal.2021.05.013_bib0157","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1158\/1078-0432.CCR-09-1920","article-title":"A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer","volume":"16","author":"Haura","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"9839","key":"10.1016\/j.survophthal.2021.05.013_bib0158","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0159","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/bjo.82.3.323","article-title":"Interferon associated retinopathy","volume":"82","author":"Hayasaka","year":"1998","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0160","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13023-020-01518-1","article-title":"Bone mineral density and bone microarchitecture in a cohort of patients with Erdheim-Chester Disease","volume":"15","author":"He","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0161","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.survophthal.2021.05.013_bib0162","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011189","article-title":"PI3K-PKB\/Akt pathway","volume":"4","author":"Hemmings","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0163","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.semarthrit.2011.11.004","article-title":"Treatment of Erdheim-Chester disease with long-term high-dose interferon-alpha","volume":"41","author":"Hervier","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.survophthal.2021.05.013_bib0164","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood-2013-12-543793","article-title":"Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation","volume":"124","author":"Hervier","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.survophthal.2021.05.013_bib0165","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00417-004-0928-5","article-title":"Erdheim-Chester disease: a case report.","volume":"242","author":"Hoffmann","year":"2004","journal-title":"Graefe's Arch Clin Exper Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0166","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2019.104320","article-title":"BRAF V600E mutations are not an oncogenic driver of solitary xanthogranuloma and reticulohistiocytoma: Testing may be useful in screening for Erdheim-Chester disease","volume":"111","author":"Hoyt","year":"2019","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0167","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ajoc.2018.07.005","article-title":"Orbital and chorioretinal manifestations of Erdheim-Chester disease treated with vemurafenib","volume":"11","author":"Huang","year":"2018","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0168","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41394-019-0234-4","article-title":"Erdheim-Chester disease mimicking lumbar nerve schwannoma: case report and literature review","volume":"5","author":"Huang","year":"2019","journal-title":"Spinal Cord Ser Cases"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0169","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/2159-8290.CD-14-0742","article-title":"Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders","volume":"5","author":"Hyman","year":"2015","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.survophthal.2021.05.013_bib0170","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0171","doi-asserted-by":"crossref","DOI":"10.1007\/s00296-020-04627-z","article-title":"Clinical presentation, imaging and response to interferon-alpha therapy in Erdheim-Chester disease: case-based review","author":"Iaremenko","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0172","first-page":"2291","article-title":"A case of retinopathy induced by intravenous administration of interferon","volume":"41","author":"Ikebe","year":"1990","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0173","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1002\/onco.13579","article-title":"Erdheim-Chester Disease and Langerhans Cell Histiocytosis: A Case of Overlap Syndrome","volume":"26","author":"Ippolito","year":"2020","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.survophthal.2021.05.013_bib0174","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1253\/circj.CJ-18-1223","article-title":"Unusual Case of Recurrent Pericardial Effusion- Erdheim-Chester Disease","volume":"83","author":"Jang","year":"2019","journal-title":"Circ J"},{"issue":"11","key":"10.1016\/j.survophthal.2021.05.013_bib0175","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.18632\/oncotarget.1964","article-title":"BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease","volume":"5","author":"Janku","year":"2014","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0176","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s10067-003-0801-7","article-title":"Improvement of Erdheim-Chester disease in two patients by sequential treatment with vinblastine and mycophenolate mofetil","volume":"23","author":"Jendro","year":"2004","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0177","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/cup.12636","article-title":"Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation","volume":"43","author":"Johnson","year":"2016","journal-title":"J Cutan Pathol"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0178","doi-asserted-by":"crossref","first-page":"555","DOI":"10.4103\/lungindia.lungindia_136_17","article-title":"Isolated pulmonary involvement in Erdheim-Chester disease","volume":"34","author":"Josan","year":"2017","journal-title":"Lung India"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0179","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000357060","article-title":"Uveitis as a result of MAP kinase pathway inhibition","volume":"4","author":"Joshi","year":"2013","journal-title":"Case Rep Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0180","first-page":"120","article-title":"Ocular surface and tear film abnormalities in women under adjuvant chemotherapy for breast cancer with the 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) regimen","volume":"17","author":"Karamitsos","year":"2013","journal-title":"Hippokratia"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0181","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.phoj.2017.09.004","article-title":"Erdheim Chester disease\u2013An unusual presentation of a rare histiocytic disease in a 3-year old boy","volume":"2","author":"Khan","year":"2017","journal-title":"Pediatr Hematol Oncol J"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0182","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.ijcard.2013.04.057","article-title":"Erdheim-Chester disease with cardiac involvement successfully treated with anakinra","volume":"167","author":"Killu","year":"2013","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0183","doi-asserted-by":"crossref","first-page":"534","DOI":"10.5468\/ogs.19232","article-title":"Retroperitoneal Erdheim-Chester disease without skeletal bone involvement mimicking uterine sarcoma with multiple organ involvement","volume":"63","author":"Kim","year":"2020","journal-title":"Obstet Gynecol Sci"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0184","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00381-015-2929-6","article-title":"Coexistence of intracranial Langerhans cell histiocytosis and Erdheim-Chester disease in a pediatric patient: a case report.","volume":"32","author":"Kim","year":"2016","journal-title":"Child's Nerv Syst"},{"issue":"10","key":"10.1016\/j.survophthal.2021.05.013_bib0185","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/ccr3.2297","article-title":"Cobimetinib-induced \"dropped head syndrome\" and subsequent disease management in an Erdheim-Chester patient","volume":"7","author":"King","year":"2019","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0186","article-title":"[Erdheim-Chester disease presenting with bilateral orbital involvement: Report of three cases].","author":"Kiratli","year":"2020","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0187","article-title":"(18)F-FDG PET\/CT versus anatomic imaging for evaluating disease extent and clinical trial eligibility in Erdheim-Chester disease: results from 50 patients in a registry study","author":"Kirchner","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0188","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s00393-018-0566-7","article-title":"[Erdheim-Chester disease: An important differential diagnosis and its main symptoms]","volume":"78","author":"Knitza","year":"2019","journal-title":"Z Rheumatol"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0189","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjd.18153","article-title":"Erdheim-Chester disease: expanding the spectrum of cutaneous manifestations","volume":"182","author":"Kobic","year":"2020","journal-title":"Br J Dermatol"},{"issue":"34","key":"10.1016\/j.survophthal.2021.05.013_bib0190","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.survophthal.2021.05.013_bib0191","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/rheumatology\/kew208","article-title":"Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes","volume":"55","author":"Kullenberg","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.survophthal.2021.05.013_bib0192","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00105-019-4460-2","article-title":"[Histiocytosis in the dermatological context of the new classification]","volume":"70","author":"Lang","year":"2019","journal-title":"Hautarzt"},{"issue":"20","key":"10.1016\/j.survophthal.2021.05.013_bib0193","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0194","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40673-020-00125-x","article-title":"Cerebellar ataxia and exercise intolerance in Erdheim-Chester disease","volume":"8","author":"Lauricella","year":"2021","journal-title":"Cerebellum Ataxias"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0195","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1308\/rcsann.2019.0130","article-title":"A rare differential for sinusitis and visual loss","volume":"102","author":"Lee","year":"2020","journal-title":"Ann R Coll Surg Engl"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0196","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4137\/CMO.S5855","article-title":"Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities","volume":"6","author":"Lemech","year":"2012","journal-title":"Clin Med Insights Oncol"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0197","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000439400","article-title":"Sarcoidosis in patients treated with vemurafenib for metastatic melanoma: a paradoxical autoimmune activation","volume":"231","author":"Lheure","year":"2015","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0198","doi-asserted-by":"crossref","first-page":"415","DOI":"10.20892\/j.issn.2095-3941.2019.0137","article-title":"Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy","volume":"16","author":"Li","year":"2019","journal-title":"Cancer Biol Med"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0199","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2165\/00003088-199732020-00003","article-title":"The clinical pharmacokinetics of cladribine","volume":"32","author":"Liliemark","year":"1997","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.survophthal.2021.05.013_bib0200","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/RLU.0b013e318156bc9b","article-title":"FDG PET\/CT for biopsy guidance in Erdheim-Chester disease","volume":"32","author":"Lin","year":"2007","journal-title":"Clin Nucl Med"},{"issue":"11","key":"10.1016\/j.survophthal.2021.05.013_bib0201","article-title":"Erdheim-Chester Disease: an unusual etiology of recurrent massive pericardial effusion","volume":"36","author":"Lin","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0202","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaa022","article-title":"Exophthalmos and coated aorta in Erdheim-Chester disease","author":"Liu","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0203","doi-asserted-by":"crossref","first-page":"682","DOI":"10.5858\/2004-128-682-MIIED","article-title":"Myocardial involvement in Erdheim-Chester disease","volume":"128","author":"Loeffler","year":"2004","journal-title":"Arch Pathol Lab Med"},{"issue":"20","key":"10.1016\/j.survophthal.2021.05.013_bib0204","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0205","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2019-000331","article-title":"Ocular side effects of antirheumatic medications: a qualitative review","volume":"5","author":"M Castillejo Becerra","year":"2020","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0206","article-title":"Erdheim-Chester disease and small lymphocytic lymphoma collision tumour presenting as a perirenal mass","volume":"2020","author":"Maietta","year":"2020","journal-title":"Case Rep Pathol"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0207","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/mdc3.12891","article-title":"Choreo-athetosis and ataxia as leading features in a case of Erdheim-Chester Disease","volume":"7","author":"Marano","year":"2020","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0208","doi-asserted-by":"crossref","DOI":"10.1093\/neuros\/nyz027","article-title":"Skull base manifestations of Erdheim-Chester Disease: A case series and systematic review","volume":"85","author":"Marinelli","year":"2019","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0209","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1019649201324","article-title":"Failure of radiation therapy for brain involvement in Erdheim Chester disease","volume":"59","author":"Mascalchi","year":"2002","journal-title":"J Neurooncol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0210","first-page":"116","article-title":"An unusual thoracic localizations of Erdheim- Chester disease: A case report","volume":"20","author":"Massaccesi","year":"2017","journal-title":"Respir Med Case Rep"},{"issue":"suppl_1","key":"10.1016\/j.survophthal.2021.05.013_bib0211","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1093\/hmg\/ddl046","article-title":"Non-coding RNA","volume":"15","author":"Mattick","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0212","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12916-014-0221-3","article-title":"Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series","volume":"12","author":"Mazor","year":"2014","journal-title":"BMC Medicine"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0213","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1750-1172-8-137","article-title":"Disease: a comprehensive review of the literature","volume":"8","author":"Mazor","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0214","doi-asserted-by":"crossref","first-page":"vdaa024","DOI":"10.1093\/noajnl\/vdaa024","article-title":"Dual BRAF\/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy","volume":"2","author":"Mazor","year":"2020","journal-title":"Neuro-Oncology Advances"},{"issue":"7504","key":"10.1016\/j.survophthal.2021.05.013_bib0215","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nature13320","article-title":"SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer","volume":"510","author":"Mazur","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0216","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/hematology.2020000159","article-title":"Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease","volume":"2020","author":"McClain","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0217","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.radonc.2006.07.034","article-title":"Palliative treatment of Erdheim-Chester disease with radiotherapy: a Rare Cancer Network study","volume":"80","author":"Miller","year":"2006","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0218","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/0002-9343(86)90694-7","article-title":"Erdheim-Chester disease. Case report and review of the literature","volume":"80","author":"Miller","year":"1986","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0219","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1212\/CPJ.0000000000000617","article-title":"Erdheim-Chester disease presenting with chorea and mimicking IgG4-related disorder","volume":"9","author":"Miron","year":"2019","journal-title":"Neurol Clin Pract"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0220","first-page":"39","article-title":"Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts","volume":"7","author":"Mirshahi","year":"2012","journal-title":"J Ophthalmic Vis Res"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0221","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/crad.2001.0681","article-title":"Erdheim-chester disease","volume":"56","author":"Murray","year":"2001","journal-title":"Clin Radiol"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0222","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/bjo.2003.035584","article-title":"Treatment of Erdheim-Chester disease with cladribine: a rational approach","volume":"88","author":"Myra","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0223","article-title":"A rare case of Erdheim-Chester disease and langerhans cell histiocytosis overlap syndrome","volume":"2015","author":"Nabi","year":"2015","journal-title":"Case Rep Pathol"},{"issue":"10","key":"10.1016\/j.survophthal.2021.05.013_bib0224","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00256-016-2447-y","article-title":"Erdheim-Chester disease with bilateral Achilles tendon involvement","volume":"45","author":"Nadjiri","year":"2016","journal-title":"Skeletal Radiol"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0225","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1167\/iovs.06-0182","article-title":"Retinal circulatory changes associated with interferon-induced retinopathy in patients with hepatitis C","volume":"48","author":"Nagaoka","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0226","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/01.rlu.0000249758.49841.fa","article-title":"Tc-99m MDP bone scintigraphy and positron emission tomography\/computed tomography (PET\/CT) imaging in Erdheim-Chester disease","volume":"32","author":"Namwongprom","year":"2007","journal-title":"Clin Nucl Med"},{"issue":"7","key":"10.1016\/j.survophthal.2021.05.013_bib0227","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/neuonc\/noaa110","article-title":"From inflammation to cancer: entering a new frontier in the management of Erdheim-Chester disease","volume":"22","author":"Nayak","year":"2020","journal-title":"Neuro-Oncol"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0228","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jdcr.2015.10.010","article-title":"Diverse cutaneous manifestations of Erdheim-Chester disease in a woman with a history of Langerhans cell histiocytosis","volume":"2","author":"Neckman","year":"2016","journal-title":"JAAD Case Reports"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0229","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1869-5760-3-32","article-title":"Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study","volume":"3","author":"Nguyen","year":"2013","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0230","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1159\/000477658","article-title":"Erdheim-Chester Disease: The importance of information integration","volume":"10","author":"Nikonova","year":"2017","journal-title":"Case Rep Oncol"},{"issue":"9","key":"10.1016\/j.survophthal.2021.05.013_bib0231","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1007\/s00330-018-5326-1","article-title":"Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF(V600E) mutation","volume":"28","author":"Nikpanah","year":"2018","journal-title":"Eur Radiol"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0232","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/archopht.1996.01100130718014","article-title":"Interferon alfa induces leukocyte capillary trapping in rat retinal microcirculation","volume":"114","author":"Nishiwaki","year":"1996","journal-title":"Arch Ophthalmol (Chicago, Ill: 1960)"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0233","first-page":"231","article-title":"[A Case report of surgical resection of a supraseller granuloma in a patient with Erdheim-Chester disease]","volume":"48","author":"Noda","year":"2020","journal-title":"No Shinkei Geka"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0234","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3988\/jcn.2020.16.2.349","article-title":"Embolic Infarction with Subdural Hemorrhage in Erdheim-Chester Disease","volume":"16","author":"Noh","year":"2020","journal-title":"J Clin Neurol (Seoul, Korea)"},{"issue":"7","key":"10.1016\/j.survophthal.2021.05.013_bib0235","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood-2016-09-740217","article-title":"Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations","volume":"129","author":"Nordmann","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0236","doi-asserted-by":"crossref","DOI":"10.1111\/j.1440-1673.2007.01821.x","article-title":"Erdheim-Chester disease: a rare cause of acute renal failure","author":"O'Rourke","year":"2007","journal-title":"Australas Radiol"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0237","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0238","article-title":"Mixed Langerhans Cell Histiocytosis and Erdheim-Chester Disease in a Girl: A Rare and Puzzling Diagnosis","author":"Ocak","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"issue":"23","key":"10.1016\/j.survophthal.2021.05.013_bib0239","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.3748\/wjg.v12.i23.3756","article-title":"Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C","volume":"12","author":"Okuse","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.survophthal.2021.05.013_bib0240","article-title":"Erdheim-Chester Disease: A Rare Clinical Entity","volume":"7","author":"Oliveira","year":"2020","journal-title":"Eur J Case Rep Intern Med"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0241","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4321\/S1885-642X2006000200001","article-title":"Ocular toxicity of systemic anticancer chemotherapy","volume":"4","author":"Omoti","year":"2006","journal-title":"Pharm Pract (Granada)"},{"issue":"12","key":"10.1016\/j.survophthal.2021.05.013_bib0242","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1634\/theoncologist.2018-0295","article-title":"FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation","volume":"23","author":"Oneal","year":"2018","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0243","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3171\/jns.2002.96.2.0344","article-title":"Multiple system Erdheim-Chester disease with massive hypothalamic-sellar involvement and hypopituitarism","volume":"96","author":"Oweity","year":"2002","journal-title":"J Neurosurg"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0244","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-230X-11-77","article-title":"Unusual manifestation of Erdheim-Chester disease","volume":"11","author":"Pan","year":"2011","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0245","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2036.2009.04071.x","article-title":"Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection","volume":"30","author":"Panetta","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0246","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217316","article-title":"Immune phenotyping of Erdheim-Chester disease through mass cytometry highlights decreased proportion of non-classical monocytes and increased proportion of Th17 cells.","author":"Papo","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.survophthal.2021.05.013_bib0247","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2017-01-761718","article-title":"High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis","volume":"130","author":"Papo","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.survophthal.2021.05.013_bib0248","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11926-019-0865-2","article-title":"Erdheim-Chester Disease: a Concise Review","volume":"21","author":"Papo","year":"2019","journal-title":"Curr Rheumatol Rep"},{"issue":"7","key":"10.1016\/j.survophthal.2021.05.013_bib0249","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.revmed.2016.10.389","article-title":"[Langerhans cell histiocytosis and Erdheim-Chester disease, a continuity?].","volume":"38","author":"Parreau","year":"2017","journal-title":"Rev Med Interne"},{"issue":"21","key":"10.1016\/j.survophthal.2021.05.013_bib0250","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1182\/blood.V124.21.5551.5551","article-title":"Cladribine for the Management of Erdheim-Chester Histiocytosis in Adults","volume":"124","author":"Patel","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.survophthal.2021.05.013_bib0251","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood.2019004478","article-title":"Long-term follow-up of mTOR inhibition for Erdheim-Chester disease","volume":"135","author":"Pegoraro","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0252","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-020-0944-4","article-title":"Erdheim-Chester disease: a rapidly evolving disease model","author":"Pegoraro","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0253","doi-asserted-by":"crossref","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","article-title":"The role of MicroRNAs in human cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0254","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2298\/VSP140915037P","article-title":"Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis","volume":"73","author":"Peric","year":"2016","journal-title":"Vojnosanit Pregl"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0255","article-title":"Choroidal mass as the first presentation of Erdheim-Chester disease","volume":"16","author":"Pichi","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"12","key":"10.1016\/j.survophthal.2021.05.013_bib0256","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jdcr.2020.10.007","article-title":"Novel insights in Erdheim-Chester disease using in vivo reflectance confocal microscopy","volume":"6","author":"Pimenta","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0257","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/WNO.0b013e31820a204e","article-title":"Presence of Erdheim-Chester disease and Langerhans cell histiocytosis in the same patient: a report of 2 cases","volume":"31","author":"Pineles","year":"2011","journal-title":"J Neuro-Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0258","first-page":"309","article-title":"Biologic agents in inflammatory eye disease","volume":"6","author":"Posarelli","year":"2011","journal-title":"J Ophthalmic Vis Res"},{"issue":"7287","key":"10.1016\/j.survophthal.2021.05.013_bib0259","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0260","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/PAS.0b013e3181d39a3d","article-title":"Erdheim-chester disease presenting as bilateral clinically malignant breast masses","volume":"34","author":"Provenzano","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0261","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1179\/1754762814Y.0000000106","article-title":"Hearing rehabilitation with a binaural cochlear implant in a patient with Erdheim-Chester disease","volume":"16","author":"Querat","year":"2015","journal-title":"Cochlear Implants Int"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0262","doi-asserted-by":"crossref","first-page":"W105","DOI":"10.1097\/RTI.0b013e31821db200","article-title":"Erdheim-Chester disease with interatrial septum involvement","volume":"27","author":"Raptis","year":"2012","journal-title":"J Thorac Imaging"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0263","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.3324\/haematol.2019.216937","article-title":"Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1","volume":"105","author":"Razanamahery","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0264","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/CCO.0b013e3283436e8c","article-title":"RAF inhibition and induction of cutaneous squamous cell carcinoma","volume":"23","author":"Robert","year":"2011","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0265","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.survophthal.2021.05.013_bib0266","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMc1111672","article-title":"Vemurafenib for melanoma metastases to the brain","volume":"365","author":"Rochet","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0267","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12883-021-02107-w","article-title":"Intracranial mass lesions and skin discoloration in the armpits as unusual clues to Erdheim-Chester disease: a case report","volume":"21","author":"Rodrigues","year":"2021","journal-title":"BMC Neurol"},{"issue":"11","key":"10.1016\/j.survophthal.2021.05.013_bib0268","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.3324\/haematol.2018.214007","article-title":"Autoimmunity associated with Erdheim-Chester disease improves with BRAF\/MEK inhibitors","volume":"104","author":"Roeser","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0269","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.18415","article-title":"Erdheim-Chester disease: how a dermatologist can help to diagnose an extremely rare serious disorder","volume":"182","author":"Rose","year":"2020","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.survophthal.2021.05.013_bib0270","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1080\/10428194.2020.1783447","article-title":"Low-dose vemurafenib monotherapy in BRAF(V600E) -mutated Erdheim-Chester disease","volume":"61","author":"Ruan","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.survophthal.2021.05.013_bib0271","first-page":"747","article-title":"Pulmonary pathology of Erdheim-Chester disease. Modern pathology: an official journal of the United States and Canadian Academy of Pathology","volume":"13","author":"Rush","year":"2000","journal-title":"Inc"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0272","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2147\/OPTH.S224672","article-title":"Multimodal Chorioretinal Imaging in Erdheim-Chester Disease","volume":"14","author":"Sacconi","year":"2020","journal-title":"Clin Ophthalmol (Auckland, NZ)."},{"key":"10.1016\/j.survophthal.2021.05.013_bib0273","article-title":"Erdheim-Chester disease with no skeletal bone involvement and massive weight loss","volume":"2017","author":"Salama","year":"2017","journal-title":"Case Rep Hematol"},{"issue":"12","key":"10.1016\/j.survophthal.2021.05.013_bib0274","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0275","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1056\/NEJMc1310849","article-title":"Efficacy of vemurafenib in hairy-cell leukemia","volume":"370","author":"Samuel","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0276","doi-asserted-by":"crossref","first-page":"118","DOI":"10.14740\/cr1025","article-title":"Erdheim-Chester disease with extensive pericardial involvement: a case report and systematic review","volume":"11","author":"Sanchez-Nadales","year":"2020","journal-title":"Cardiol Res"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0277","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.010123","article-title":"Multisystem Erdheim-Chester disease with extensive pericardial and vascular involvement","volume":"13","author":"S\u00e1nchez-Nadales","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0278","article-title":"Bilateral Renal Colic as an Initial Presentation of Erdheim-Chester Disease","volume":"2019","author":"Sarkis","year":"2019","journal-title":"Case Rep Urol"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0279","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12886-017-0541-0","article-title":"Ocular toxicity due to Trametinib and Dabrafenib","volume":"17","author":"Sarny","year":"2017","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0280","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1634\/theoncologist.2019-0606","article-title":"Real-World Toxicity Experience with BRAF\/MEK Inhibitors in Patients with Erdheim-Chester Disease","volume":"25","author":"Saunders","year":"2020","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.survophthal.2021.05.013_bib0281","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1182\/blood.V93.12.4125","article-title":"Cladribine activity in adult langerhans-cell histiocytosis","volume":"93","author":"Saven","year":"1999","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0282","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/IOP.0000000000001533","article-title":"Clinical-radiological patterns and histopathological outcomes in non-thyroid extraocular muscle enlargement: retrospective case series and current concepts","volume":"36","author":"Savino","year":"2020","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0283","article-title":"Bilateral multifocal central serous-like chorioretinopathy due to MEK inhibition for metastatic cutaneous melanoma","volume":"2013","author":"Schoenberger","year":"2013","journal-title":"Case Rep Ophthalmol Med"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0284","first-page":"1550","article-title":"Coated aorta\": a new sign of Erdheim-Chester disease","volume":"27","author":"Serratrice","year":"2000","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0285","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00000441-200101000-00010","article-title":"Erdheim-Chester disease: a rare multisystem histiocytic disorder associated with interstitial lung disease","volume":"321","author":"Shamburek","year":"2001","journal-title":"Am J Med Sci"},{"issue":"12","key":"10.1016\/j.survophthal.2021.05.013_bib0286","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1097\/IAE.0000000000000624","article-title":"Long-term efficacy of systemic infliximab in recalcitrant retinal vasculitis","volume":"35","author":"Sharma","year":"2015","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"Pt 4","key":"10.1016\/j.survophthal.2021.05.013_bib0287","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/eye.2000.151","article-title":"Erdheim-Chester disease: two cases of orbital involvement","volume":"14","author":"Sheidow","year":"2000","journal-title":"Eye (London, England)"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0288","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0289","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1001\/archopht.1991.01080060114037","article-title":"Orbital and eyelid involvement with Erdheim-Chester disease. A report of two cases","volume":"109","author":"Shields","year":"1991","journal-title":"Arch Ophthalmol (Chicago, Ill: 1960)"},{"issue":"8","key":"10.1016\/j.survophthal.2021.05.013_bib0290","doi-asserted-by":"crossref","first-page":"e00475","DOI":"10.1002\/rcr2.475","article-title":"Erdheim-Chester disease progression from miliary pulmonary nodules to large tumours","volume":"7","author":"Shiihara","year":"2019","journal-title":"Respirol Case Rep"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0291","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10384-004-0176-6","article-title":"Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography","volume":"49","author":"Shimura","year":"2005","journal-title":"Jpn J Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2021.05.013_bib0292","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/art.34409","article-title":"Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes","volume":"64","author":"Sibley","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0293","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/clpt.1985.16","article-title":"Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration","volume":"37","author":"Smith","year":"1985","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.survophthal.2021.05.013_bib0294","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1056\/NEJMcibr1013704","article-title":"Resistance to BRAF inhibition in melanomas","volume":"364","author":"Solit","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0295","article-title":"Erdheim-Chester disease with concurrent lung adenocarcinoma","volume":"8","author":"Solomon","year":"2020","journal-title":"J Investig Med High Impact Case Rep"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0296","doi-asserted-by":"crossref","DOI":"10.1016\/j.joms.2021.01.009","article-title":"Oral findings of Erdheim-Chester disease: a case report and review of the literature.","author":"Sorenson","year":"2021","journal-title":"J Oral Maxillofac Surg"},{"issue":"11","key":"10.1016\/j.survophthal.2021.05.013_bib0297","first-page":"5953","article-title":"Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study","volume":"46","author":"Spriggs","year":"1986","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0298","doi-asserted-by":"crossref","first-page":"714","DOI":"10.4103\/idoj.IDOJ_65_19","article-title":"Adult Onset Xantogranulomatous Disease Associated with Vitiligo","volume":"10","author":"Sriram","year":"2019","journal-title":"Ind Dermatol Online J"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0299","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101510","article-title":"Erdheim-Chester disease","author":"Starkebaum","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101510","article-title":"Erdheim-Chester disease","volume":"34","author":"Starkebaum","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0301","first-page":"55","article-title":"Erdheim-Chester disease, moving away from the orphan diseases: A case report","volume":"20","author":"Stempel","year":"2017","journal-title":"Respir Med Case Rep"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0302","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1055\/s-2006-926593","article-title":"[Interferon causes ischemic ocular diseases\u2013case studies and review of the literature]","volume":"223","author":"Stoffelns","year":"2006","journal-title":"Klin Monatsbl Augenheilkd"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0303","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0304","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuroscience.2016.11.017","article-title":"Molecular neurobiology of mTOR","volume":"341","author":"Switon","year":"2017","journal-title":"Neuroscience"},{"issue":"24","key":"10.1016\/j.survophthal.2021.05.013_bib0305","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2169\/internalmedicine.54.4967","article-title":"Intrapelvic Bulky tumor as an unusual presentation of Erdheim-Chester disease","volume":"54","author":"Taguchi","year":"2015","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0306","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1507\/endocrj.K07E-044","article-title":"Erdheim-Chester disease: report of a case with PCR-based analysis of the expression of osteopontin and survivin in Xanthogranulomas following glucocorticoid treatment","volume":"55","author":"Taguchi","year":"2008","journal-title":"Endocr J"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0307","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3960\/jslrt.18015","article-title":"Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: A case report","volume":"58","author":"Tamura","year":"2018","journal-title":"J Clin Exp Hematopathol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0308","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ajo.2017.01.017","article-title":"Three cases of Erdheim-Chester disease with intraocular manifestations: imaging and histopathology findings of a rare entity","volume":"176","author":"Tan","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0309","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3171\/jns.2004.101.3.0521","article-title":"Diagnosis of Erdheim-Chester disease by using computerized tomography-guided stereotactic biopsy of a caudate lesion. Case report","volume":"101","author":"Tashjian","year":"2004","journal-title":"J Neurosurg"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0310","article-title":"Erdheim-Chester disease presenting with diplopia: a challenging diagnosis with effective treatment","author":"Tavakoli","year":"2020","journal-title":"J Neuro-Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0311","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/MPH.0000000000001538","article-title":"Effective High-dose Interferon-\u03b1 therapy in a 13-Year-Old Girl With Erdheim-Chester Disease","volume":"42","author":"Tezol","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0312","first-page":"1267","article-title":"MR of diabetes insipidus in a patient with Erdheim-Chester disease: case report","volume":"11","author":"Tien","year":"1990","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0313","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.105841","article-title":"Erdheim-Chester disease: A challenging diagnosis for an effective therapy","volume":"194","author":"Todisco","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"issue":"12","key":"10.1016\/j.survophthal.2021.05.013_bib0314","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1097\/TP.0000000000000551","article-title":"Everolimus-induced posterior reversible encephalopathy syndrome and bilateral optic neuropathy after kidney transplantation","volume":"98","author":"Touhami","year":"2014","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.survophthal.2021.05.013_bib0315","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/MPH.0b013e3181b76827","article-title":"Erdheim-Chester disease in childhood: a challenging diagnosis and treatment","volume":"31","author":"Tran","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"issue":"12","key":"10.1016\/j.survophthal.2021.05.013_bib0316","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1002\/art.30638","article-title":"Treatment of pediatric Erdheim-Chester disease with interleukin-1-targeting drugs","volume":"63","author":"Tran","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0317","first-page":"529","article-title":"Endocrine manifestations of Erdheim-Chester disease (a distinct form of histiocytosis)","volume":"244","author":"Tritos","year":"1998","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0318","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0006-291X(88)81104-5","article-title":"Inhibition of in vitro angiogenesis by lymphotoxin and interferon-gamma","volume":"155","author":"Tsuruoka","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0319","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13104-015-1135-7","article-title":"Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report","volume":"8","author":"Tzoulis","year":"2015","journal-title":"BMC Res Notes"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0320","first-page":"115","article-title":"Unilateral leg edema: Erdheim-Chester disease","volume":"113","author":"Uliel","year":"2020","journal-title":"QJM"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0321","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/PAT.0b013e32834685d5","article-title":"Erdheim-Chester disease with extensive coronary arterial involvement","volume":"43","author":"Vaideeswar","year":"2011","journal-title":"Pathology"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0322","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0323","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/0284186X.2019.1589648","article-title":"Sirolimus monotherapy for Erdheim-Chester disease","volume":"58","author":"van Bommel","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0324","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2147\/OTT.S121615","article-title":"Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim-Chester disease","volume":"10","author":"Varadi","year":"2017","journal-title":"OncoTarget Ther"},{"issue":"15","key":"10.1016\/j.survophthal.2021.05.013_bib0325","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2165\/00003495-200363150-00003","article-title":"Neurotoxic Complications of Chemotherapy in Patients with Cancer","volume":"63","author":"Verstappen","year":"2003","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0326","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00005792-199605000-00005","article-title":"Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases","volume":"75","author":"Veyssier-Belot","year":"1996","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0327","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2214\/AJR.19.21523","article-title":"Multisystemic Imaging Findings in Chinese Patients With Erdheim-Chester Disease","volume":"213","author":"Wang","year":"2019","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0328","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1080\/0284186X.2019.1670355","article-title":"Successful treatment of central nervous system involved Erdheim-Chester disease by intermediate-dose cytarabine as first-line therapy","volume":"59","author":"Wang","year":"2020","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0329","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.clinimag.2019.10.001","article-title":"Neuroimaging features of CNS histiocytosis syndromes","volume":"60","author":"Wang","year":"2020","journal-title":"Clin Imaging"},{"issue":"11","key":"10.1016\/j.survophthal.2021.05.013_bib0330","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113240","article-title":"The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester Disease","volume":"12","author":"Weissman","year":"2020","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.survophthal.2021.05.013_bib0331","first-page":"834","article-title":"Erdheim-Chester disease in a child","volume":"61","author":"Wen","year":"2012","journal-title":"West Indian Med J"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0332","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0333","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.urology.2004.10.051","article-title":"Compression of kidneys in Erdheim-Chester disease of retroperitoneum: Open surgical approach","volume":"65","author":"Wimpissinger","year":"2005","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0334","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2012.06.023","article-title":"Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic Therapy (SABER) Study","volume":"155","author":"Winthrop","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0335","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/1471-2407-13-561","article-title":"Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma","volume":"13","author":"Wolf","year":"2013","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0336","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/jnnp.66.1.72","article-title":"Neurological manifestations of Erdheim-Chester disease","volume":"66","author":"Wright","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0337","first-page":"163","article-title":"A case of Erdheim-Chester disease with bilateral orbital involvement","volume":"17","author":"Wu","year":"2001","journal-title":"Yan Ke Xue Bao"},{"issue":"3","key":"10.1016\/j.survophthal.2021.05.013_bib0338","doi-asserted-by":"crossref","first-page":"614","DOI":"10.12998\/wjcc.v8.i3.614","article-title":"Erdheim-Chester disease with asymmetric talus involvement: A case report","volume":"8","author":"Xia","year":"2020","journal-title":"World J Clin Cases"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0339","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/ceo.13665","article-title":"Erdheim-Chester disease with bilateral choroidal infiltration","volume":"48","author":"Xiao","year":"2020","journal-title":"Clin Experiment Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2021.05.013_bib0340","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2169\/internalmedicine.3324-19","article-title":"Erdheim-Chester Disease.","volume":"59","author":"Yamamoto","year":"2020","journal-title":"Intern Med"},{"issue":"6","key":"10.1016\/j.survophthal.2021.05.013_bib0341","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2217\/imt-2019-0150","article-title":"Erdheim-Chester disease: a case treated with IFN-\u03b1 monitored using plasma and urine cell-free DNA","volume":"12","author":"Yang","year":"2020","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.survophthal.2021.05.013_bib0342","first-page":"43","article-title":"[A case of Erdheim-Chester disease effectively treated by cyclophosphamide and prednisolone]","volume":"45","author":"Yano","year":"2007","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0343","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2008.12.004","article-title":"Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma","volume":"116","author":"Yeh","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2021.05.013_bib0344","article-title":"Kidney Transplantation for Erdheim-Chester Disease","volume":"2020","author":"Yoo","year":"2020","journal-title":"Case Rep Transplant"},{"issue":"12","key":"10.1016\/j.survophthal.2021.05.013_bib0345","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jdcr.2019.09.018","article-title":"A case of generalized xanthogranuloma with systemic involvement","volume":"5","author":"Yoon","year":"2019","journal-title":"JAAD Case Reports"},{"issue":"5","key":"10.1016\/j.survophthal.2021.05.013_bib0346","doi-asserted-by":"crossref","first-page":"774","DOI":"10.2967\/jnumed.117.200741","article-title":"(18)F-FDG PET\/CT in Erdheim-Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker","volume":"59","author":"Young","year":"2018","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.survophthal.2021.05.013_bib0347","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/cpdd.773","article-title":"Absolute Bioavailability of Vemurafenib in Patients With BRAF(V600) Mutation-Positive Malignancies","volume":"9","author":"Zhang","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"10.1016\/j.survophthal.2021.05.013_bib0348","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625721001375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625721001375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:55:51Z","timestamp":1758542151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625721001375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":348,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0039625721001375"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2021.05.013","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2021.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}